It has also been reported that targeted disruption of NLK inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma (60), which implies the anti-tumor activity of miR-101. Here, CDK2 is linked to neoplasm.